[To the problem of extended serological testing for viral hepatitis B in rheumatoid arthritis patients].

IF 0.3 4区医学 Q3 MEDICINE, GENERAL & INTERNAL

Terapevticheskii Arkhiv Pub Date : 2025-06-08 DOI:10.26442/00403660.2025.05.203214

G I Gridneva, B S Belov, Z G Verizhnikova, E S Aronova, E Y Samarkina, T S Panevin, T A Lisitsyna, G V Lukina

{"title":"[To the problem of extended serological testing for viral hepatitis B in rheumatoid arthritis patients].","authors":"G I Gridneva, B S Belov, Z G Verizhnikova, E S Aronova, E Y Samarkina, T S Panevin, T A Lisitsyna, G V Lukina","doi":"10.26442/00403660.2025.05.203214","DOIUrl":null,"url":null,"abstract":"Aim: The objectives of the study: to conduct serologic screening for latent HBV infection in rheumatoid arthritis (RA) patients, to determine the level of protective antibodies to HBsAg in RA patients, and to determine the clinical and laboratory features of RA patients with latent hepatitis B in the course of retrospective analysis.Materials and methods: 440 HBsAg-negative RA patients over 18 years old were included in the study. Blood serum was analyzed for the presence of antibodies to HBcAg (anti-HBc) by semi-quantitative method and the content of antibodies to HBsAg by quantitative method. Patients were included in the study consecutively, the inclusion criterion was negative HBsAg test, the exclusion criteria were co-infection with hepatitis C virus or HIV.Results: It was found that 64 (14%) patients were anti-HBs positive, in this group more than half [39 (61%)] had no antibodies to HBsAg (anti-HBs) in protective titer (more than 10 IU/mL), and 26 patients had no anti-HBs at all. Overall, only 130 (30%) patients in the cohort had anti-HBs in protective titer. Retrospective analysis of case histories and outpatient records revealed 33 cases of transaminase elevation, and in 15 patients this adverse event was the cause of antirheumatic drug withdrawal. Clinically significant thrombocytopenia occurred in 10 patients.Conclusion: Extended HBV screening for RA patients showed the absence of anti-HBV protection in 70% of patients. Latent HBV [HBsAg(-)/anti-HBc(+)] was detected in 14% of patients. It is necessary to be alert to cases of combined elevation of ALT and/or AST and thrombocytopenia as symptoms of probable exacerbation of HBV infection.","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"97 5","pages":"443-448"},"PeriodicalIF":0.3000,"publicationDate":"2025-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Terapevticheskii Arkhiv","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.26442/00403660.2025.05.203214","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: The objectives of the study: to conduct serologic screening for latent HBV infection in rheumatoid arthritis (RA) patients, to determine the level of protective antibodies to HBsAg in RA patients, and to determine the clinical and laboratory features of RA patients with latent hepatitis B in the course of retrospective analysis.

Materials and methods: 440 HBsAg-negative RA patients over 18 years old were included in the study. Blood serum was analyzed for the presence of antibodies to HBcAg (anti-HBc) by semi-quantitative method and the content of antibodies to HBsAg by quantitative method. Patients were included in the study consecutively, the inclusion criterion was negative HBsAg test, the exclusion criteria were co-infection with hepatitis C virus or HIV.

Results: It was found that 64 (14%) patients were anti-HBs positive, in this group more than half [39 (61%)] had no antibodies to HBsAg (anti-HBs) in protective titer (more than 10 IU/mL), and 26 patients had no anti-HBs at all. Overall, only 130 (30%) patients in the cohort had anti-HBs in protective titer. Retrospective analysis of case histories and outpatient records revealed 33 cases of transaminase elevation, and in 15 patients this adverse event was the cause of antirheumatic drug withdrawal. Clinically significant thrombocytopenia occurred in 10 patients.

Conclusion: Extended HBV screening for RA patients showed the absence of anti-HBV protection in 70% of patients. Latent HBV [HBsAg(-)/anti-HBc(+)] was detected in 14% of patients. It is necessary to be alert to cases of combined elevation of ALT and/or AST and thrombocytopenia as symptoms of probable exacerbation of HBV infection.

查看原文本刊更多论文

[关于类风湿关节炎患者扩大乙型病毒性肝炎血清学检测的问题]。

目的：本研究的目的是：对类风湿关节炎（RA）患者进行潜伏性HBV感染的血清学筛查，确定类风湿关节炎（RA）患者的HBsAg保护性抗体水平，并在回顾性分析过程中确定类风湿关节炎（RA）患者潜伏性乙型肝炎的临床和实验室特征。材料与方法：纳入年龄在18岁以上的440例hbsag阴性RA患者。采用半定量法检测血清中HBcAg抗体的存在情况，采用定量法检测血清中HBsAg抗体的含量。患者连续纳入研究，纳入标准为HBsAg阴性，排除标准为合并丙型肝炎病毒或HIV感染。结果：64例（14%）患者抗- hbs阳性，其中超过半数[39例（61%）]患者无HBsAg（抗- hbs）保护效价（大于10 IU/mL）的抗体，26例患者无抗- hbs。总体而言，该队列中只有130例（30%）患者具有保护滴度的抗hbs。回顾性分析病例史和门诊记录显示33例转氨酶升高，其中15例患者因转氨酶升高导致停药。10例患者出现明显的临床血小板减少。结论：扩大对RA患者的HBV筛查显示70%的患者缺乏抗HBV保护。在14%的患者中检测到潜伏型HBV [HBsAg(-)/抗- hbc(+)]。有必要警惕ALT和/或AST联合升高和血小板减少作为HBV感染可能加重的症状。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Terapevticheskii Arkhiv 医学-医学：内科

CiteScore

1.40

自引率

33.30%

发文量

171

审稿时长

3-8 weeks

期刊介绍： Терапевтический архив The journal was founded by the prominent Russian therapists M.P. Konchalovsky and G.F. Lang in 1923. Then its editors-in-chief were Professors V.N. Vinogradov and A.G. Gukasyan. Since 1972, E.I. Chazov, Academician of the Russian Academy of Sciences, has been heading the editorial board of the journal. Over 90 years, there have been more than 1000 issues where the authors and editorial staff have done their best for readers to keep abreast of current advances in medical science and practice and for physicians to master the advanced principles of recognition and treatment of a wide spectrum of visceral diseases. The papers published in the journal (editorials, original articles, lectures, reviews, etc.) cover both current scientific achievements and practical experience in diagnosing, treating, and preventing visceral diseases. The authors of publications are not only Russian, but also foreign scientists and physicians. All papers are peer-reviewed by highly qualified Russian specialists. The journal is published monthly. Traditionally, each issue has predominantly certain thematic areas covering individual therapy specializations. Every year, one of the issues is devoted to related problems in practical medicine (allergology and immunology, neurology and psychiatry, obstetrics, oncology, etc.). This all draws the attention of the reading public to the journal. The journal is indexed in RSCI (Russian Science Citation Index), PubMed/Medline, Index Medicus, Scopus/EMBASE, Web of Science Core Collection (Science Citation Index Expanded), Web of Science (Russian Science Citation Index - RSCI, Current Contents Connect, BIOSIS Previews), Google Scholar, Ulrich''s Periodicals Directory. The journal is included in the list of periodicals recommended by the Higher Attestation Committee for publishing the papers containing the basic materials of doctoral and candidate dissertations. By the decision of the Presidium of the Russian Academy of Medical Sciences, the “Therapevticheskiy Arkhiv” was awarded the Botkin medal. It was admitted to the European Association of Sciences Editors (EASE). The journal was honored with the Golden Press Fund decoration at the 13th International Press Professional Exhibition.